ϩ -Cl Ϫ cotransporter (NCC) in the distal convoluted tubule (DCT) of the kidney is a key determinant of Na ϩ balance. Disturbances in NCC function are characterized by disordered volume and blood pressure regulation. However, many details concerning the mechanisms of NCC regulation remain controversial or undefined. This is partially due to the lack of a mammalian cell model of the DCT that is amenable to functional assessment of NCC activity. Previously reported investigations of NCC regulation in mammalian cells have either not attempted measurements of NCC function or have required perturbation of the critical without a lysine kinase (WNK)/STE20/ SPS-1-related proline/alanine-rich kinase regulatory pathway before functional assessment. Here, we present a new mammalian model of the DCT, the mouse DCT15 (mDCT15) cell line. These cells display native NCC function as measured by thiazide-sensitive, Cl Ϫ -dependent 22 Na ϩ uptake and allow for the separate assessment of NCC surface expression and activity. Knockdown by short interfering RNA confirmed that this function was dependent on NCC protein. Similar to the mammalian DCT, these cells express many of the known regulators of NCC and display significant baseline activity and dimerization of NCC. As described in previous models, NCC activity is inhibited by appropriate concentrations of thiazides, and phorbol esters strongly suppress function. Importantly, they display release of WNK4 inhibition of NCC by small hairpin RNA knockdown. We feel that this new model represents a critical tool for the study of NCC physiology. The work that can be accomplished in such a system represents a significant step forward toward unraveling the complex regulation of NCC. sodium-chloride cotransporter; STE20/SPS-1-related proline/alaninerich kinase; with-no-lysine kinase 4 THE NA ϩ -CL Ϫ COTRANSPORTER (NCC) in the distal convoluted tubule (DCT) of the kidney is known to be a key determinant of Na ϩ balance, reabsorbing 5-10% of the total filtered load of Na ϩ in the kidney (12). Disturbances in NCC function are characterized by disordered total body volume regulation and, therefore, disturbed blood pressure regulation. This is evidenced not only by the efficacy of thiazide diuretics but also by the hypotension seen with loss of NCC function (Gitelman's syndrome) and the hypertension seen with increases in NCC activity [familial hyperkalemic hypertension (FHHt)] (4, 18, 27, 33, 36) . Investigation into the mechanism behind FHHt led to the discovery of a major regulatory pathway for NCC, as mutations in with-no-lysine kinase (WNK)1 and WNK4 were found to be linked to FHHt (36). A flurry of work followed, describing a cascade of inhibitory effects involving WNKs and NCC (22, (37) (38) (39) . NCC activity is inhibited by WNK4, with WNK1 inhibiting WNK4's effect (37-39). Further studies went on to link two kinases, STE20/SPS-1-related proline/ alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR)1, to this pathway, acting as downstream targets for the WNKs that go on to phosphorylate NCC itself.
THE NA
ϩ -CL Ϫ COTRANSPORTER (NCC) in the distal convoluted tubule (DCT) of the kidney is known to be a key determinant of Na ϩ balance, reabsorbing 5-10% of the total filtered load of Na ϩ in the kidney (12) . Disturbances in NCC function are characterized by disordered total body volume regulation and, therefore, disturbed blood pressure regulation. This is evidenced not only by the efficacy of thiazide diuretics but also by the hypotension seen with loss of NCC function (Gitelman's syndrome) and the hypertension seen with increases in NCC activity [familial hyperkalemic hypertension (FHHt)] (4, 18, 27, 33, 36) . Investigation into the mechanism behind FHHt led to the discovery of a major regulatory pathway for NCC, as mutations in with-no-lysine kinase (WNK)1 and WNK4 were found to be linked to FHHt (36) . A flurry of work followed, describing a cascade of inhibitory effects involving WNKs and NCC (22, (37) (38) (39) . NCC activity is inhibited by WNK4, with WNK1 inhibiting WNK4's effect (37) (38) (39) . Further studies went on to link two kinases, STE20/SPS-1-related proline/ alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR)1, to this pathway, acting as downstream targets for the WNKs that go on to phosphorylate NCC itself.
However, despite these advances, many details concerning the mechanisms of regulation of this cotransporter in the mammalian kidney remain either controversial or undefined. This has been primarily due to the lack of a mammalian cell model that is amenable to functional assessment of NCC activity and the difficulty in isolating this segment for microperfusion studies. Thus, investigations to date have used primarily whole animal studies (conventional experimental models as well as transgenic strategies) or the Xenopus laevis oocyte expression system. These essential studies have formed the basis of our knowledge about regulation of the cotransporter. There have been some studies using mammalian cells to examine the regulation of NCC. A number of these studies focused on surface expression of the cotransporter and did not examine activity (2, 34, 41) . These studies examined the regulation of the cotransporter by WNK4, which predominantly appears to regulate NCC through changes in surface expression. Recent investigations have indicated that NCC can also be regulated by increases of in situ cotransporter activity in the Xenopus laevis oocyte expression system (8, 19, 30) . In fact, whether SPAK increases NCC activity via increases in NCC surface expression, in situ activity, or both remains unclear (20) . Thus, the ability to assess activity independent of surface expression would be a critical step forward. To our knowledge, the few models that have attempted measurement of NCC activity (thiazide-sensitive 22 Na ϩ uptake) in mammalian cells have used Cl Ϫ -free preincubations, presumably to obtain an adequate signal above baseline (5, 7, 15, 16, 23, 24, 31) . Since Cl Ϫ -free or low-Cl Ϫ incubations have been shown to activate SPAK and OSR1, these models are not ideally suited to studying influences on NCC activity, which may be mediated by OSR1/SPAK (31) . Therefore, a mammalian DCT cell line in which NCC activity can be reliably measured without need of a Cl Ϫ -free preincubation is needed. We have now developed and fully characterized a new model of the DCT: mouse DCT15 (mDCT15) cells. Similar to the mammalian DCT, this cell line natively expresses all of the known key regulators of NCC and displays a constitutive activity of NCC that is suppressed by WNK4 at baseline.
MATERIALS AND METHODS
Materials. All materials were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise.
Cell culture and treatments. mDCT or mDCT15 cells were plated on cell culture dishes and grown in growth medium containing a 50:50 mix of DMEM-F-12, 5% heat-inactivated FBS, and 1% penicillinstreptomycin-neomycin (PSN) at 37°C. Experiments were conducted when the cells reached 90 -95% confluence.
Assessment of NCC function in mDCT and mDCT15 cells. mDCT and mDCT15 cells were seeded in 12-well plates and prepared as described above. Cells were then incubated in a serum-free growth media (Opti-Mem) for 24 h before being assayed. Thirty minutes before uptake, 0.1 mM metolazone was added to the media in the thiazide-treated groups. For Cl Ϫ -free preincubation experiments, cells were incubated in Cl Ϫ -free media [130 mM Na-gluconate, 2 mM K-gluconate, 1.0 mM Ca-gluconate, 1 mM Mg-gluconate, 5 mM HEPES-Tris (pH 7.4), 1 mM amiloride, and 0.1 mM bumetanide] during this 30-min time period. The medium was then changed to 22 Na ϩ -containing medium [140 mM NaCl, 1 mM CaCl, 1 mM MgCl, 5 mM HEPES-Tris (pH 7.4), 1 mM amiloride, 0.1 mM bumetanide, 0.1 mM benzamil, 1 mM ouabain, and 1 Ci/ml 22 Na ϩ ] with or without thiazide (0.1 mM metolazone) and incubated for 20 min. Tracer uptake was then stopped via washes with ice-cold wash buffer. Cells were subsequently lysed with 0.1% SDS. Radioactivity was measured via liquid scintillation, and protein concentrations of the lysates were determined (BCA protein assay, Pierce). Uptakes were normalized to nanomoles per milligram. Thiazide-sensitive uptake was given by the difference of the uptakes with and without thiazide.
Cell surface biotinylation. mDCT and mDCT15 cells were incubated as described above. Cells were washed with PBS, and cell surface proteins were labeled with sulfo-NHS-SS-biotin (Pierce, Rockford, IL) in PBS for 30 min at 4°C. The reaction was quenched by adding 500 l of the quenching solution (Pierce). Cells were harvested, lysed using lysis buffer containing protease inhibitor, and homogenized by sonication on ice. Cell lysates were centrifuged briefly, and the supernatant was collected. Supernatant (80 l) from each group was stored separately at Ϫ80°C. Biotinylated proteins in the cell lysates were isolated by an incubation with NeutrAvidin gel (Pierce) for 60 min at room temperature. Labeled proteins were washed four times and eluted in SDS-PAGE sample buffer containing 50 mM DTT as per protocol outlined in the Pierce Surface Protein Isolation kit. Protein concentrations were determined using the BCA protein assay kit (Pierce). The eluted proteins and cell lysates were immunoblotted as detailed below.
NCC antibody generation. An NCC amino-terminal peptide sequence (PGEPRKVRPTLADLHSFLKQEGC) was provided to Pocono Rabbit Farms and Laboratory for antigen generation. The peptide was generated, conjugated to keyhole limpet hemocyanin, and injected into rabbits according to their protocol. Sequential bleeds were screened by ELISA, yielding an appropriate serum sample. The serum was then affinity purified utilizing a column with the immunizing peptide. Immunoblot analyses and Immunohistochemistry were done to confirm the specificity of the immunopurified antibody.
Immunoblot analysis. mDCT and mDCT15 cells were incubated as described above. Cells were harvested, lysed using lysis buffer containing protease inhibitor, and homogenized by sonication on ice. Cell lysates were centrifuged briefly, and the supernatant was collected. Proteins were transferred electrophoretically to polyvinylidene difluoride membranes. After being blocked with 3% BSA, membranes were probed with the corresponding primary antibodies [SPAK N17 (Santa Cruz Biotechnology, 1:1,000), phospho-SPAK 373 (Division of Signal Transduction Therapy, University of Dundee, 2.5 l/ml ϩ 1 l nonphosphorylated peptide), NCC (1:1,000), T53 phospho-NCC (a gift from David Ellison, 1:1,000), WNK4 (Division of Signal Transduction Therapy, University of Dundee, 5 g/ml), and actin (Santa Cruz Biotechnology, 1:1,000)] overnight at 4°C. Blots were washed in Tris-buffered saline-Tween 20. Signal detection was done via either the Odyssey infrared imaging system (Li-Cor Biosciences) or chemiluminescence. For the Odyssey system, the secondary antibodies used were IRDye680 goat anti-mouse (Rockland Immunochemicals, dilution: 1:10,000) and then subsequent scanning of the membrane by the Odyssey infrared imager. Intensity of the protein bands was analyzed using Odyssey infrared imaging software (Li-Cor Biosciences). For chemiluminescence, the secondary antibodies were donkey anti-rabbit horseradish peroxidase-linked antibody (Amersham, 1:5,000) and donkey anti-sheep horseradish peroxidase-linked antibody (Abcam, 1:3,000). Supersignal West Pico was used for chemiluminescence (Thermo Scientific). Chemiluminescence was detected with G:Box gelbox (Syngene) and analysis by Genetools software (Syngene).
Statistical analysis. Statistical analysis was performed using the SigmaPlot software package (Systat, San Jose, CA). Data were analyzed for statistical significance using ANOVA (Holm-Sidak) or a Mann-Whitney rank-sum test where appropriate. P values of Ͻ0.05 were taken as statistically significant.
Generation of mDCT15 cells. mDCT cells (a gift from Peter Friedman) were dilutely plated, and single colonies were isolated via cloning rings. Individual colonies were screened for NCC mRNA expression greater than or equal to the original mDCT cells using real-time PCR. NCC activity of clones with NCC mRNA expression was determined via 22 Na ϩ uptake as described above. Short interfering RNA NCC transfection protocol. mDCT cells were cultured at 37°C in 5% CO 2 in DMEM-F-12 (50:50) supplemented with 5% FBS and 1% PSN. Cells were plated in a 12-well tissue culture plate and grown to 50% confluency. GeneSilencer reagent was prepared by dilution in serum-free medium. The short interfering (si)RNA solution was prepared by mixing the diluent, serum-free medium, and 600 ng of siRNA specific for NCC (s73841, Ambion) or nontargeting control (4404020, Ambion). The two solutions were combined and incubated at room temperature for 15 min. The siRNA/GeneSilencer mix was added to the cells grown in serum-containing medium. Cells were incubated for 24 h before fresh medium was added. Forty-eight hours after transfection, cells were lysed, and protein was collected.
Lentiviral transduction. mDCT cells were cultured at 37°C in 5% CO2 in DMEM-F-12 (50:50) supplemented with 5% FBS and 1% PSN. Cells were plated in a 96-well microtest tissue culture plate at a density of 2.5 ϫ 10 3 cells/well. At 24 h after cell plating, hexadimethrine bromide was added to the medium at a final concentration of 8 g/ml, and cells were transduced with WNK4 Mission lentiviral transduction particles (12220910MN, Sigma) or nontargeting transduction particles (SHC002, Sigma). Medium containing viral particles was removed the following day and replaced with medium containing puromycin at a final concentration of 1 g/ml. Medium was aspirated every 3 days and replaced with fresh puromycin-containing medium for 1 wk.
Real-time PCR. First-strand cDNA synthesis was carried out with the Superscript VILO cDNA synthesis kit (Invitrogen). A 20-l reaction was preformed following the manufacturer's protocol using 2.5 g RNA. The resulting cDNA was diluted 1:5 in RNase-free water. Real-time quantitative PCR using SYBR GreenER qPCR SuperMix for ABI PRISM (Invitrogen) was performed in duplicate for each sample. An AB7300 was programmed as follows: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 60 s, and melting curve analysis was then performed.
RT-PCR. One-step RT-PCR was performed in a 50-l reaction using Superscript One-Step RT-PCR with Platinum Taq (Invitrogen) according to the manufacturer's protocol. Thermocycling was performed under the following conditions: 30 min at 55°C (cDNA synthesis), 2 min at 94°C (predenaturation), 55 cycles of 15 s at 94°C (denaturation), 30 s at 58°C (annealing), and 1 min for 72°C (extension), and a final extension for 1 cycle of 5 min at 72°C. Samples were then run on a 2% agarose gel with ethidum bromide at 120 V for 30 min. UV light was used to analyze the results. The primers used were as follows: WNK1, sense 5=-CATCTG-GAACACTTAAGACGTACTT-3= and antisense 5=-CACCAGCTTCT-TAAAACTTTGATTT-3=; WNK3, sense 5=-GAGCCAGCTAGCACA-GAAGATTCTGAGA-3= and antisense 5= TATTCTCGCTTCTACA-GTCAGAGGGGCA-3=; WNK4, sense 5=-TGGTCTCAACCAGCCTC-ACTCCTT-3= and antisense 5=-GGTTCTTTAGAGCTTGAAGGTGG-GC-3=; OSR, sense 5=-TTTCTCAGCTGAGGTCTCCCCG-3= and antisense 5=-TGCCATCATCAGGAATATCCGAGCC-3=; epithelial Na ϩ channel (ENaC)-␣, sense 5=-GGCAGCCCACCGAGGAGGA-3= and antisense 5=-GCCACAGCACCGCCCAGAA-3=; ENaC-␤, sense 5=-CC-GATGTTGCCATAAAGAACCT-3= and antisense 5=-CTCTGGTCCC-GCTCCTGAGAC-3=; ENaC-␥, sense 5=-CGCCCTCCTCGTCTTCTC-TTTC-3= and antisense 5=-TGGCCTTTCCCTTCTCGTTCTC-3=; mineralocorticoid receptor (MR), sense 5=-TCCAAAGGATGGCCTC-AAA-3= and antisense 5=-ATCTTTCTCAGCTCCTTGATGTAATTT-3=; and serum-and glucocorticoid-inducible kinase (SGK)-1, sense 5=-TGTCTTGGGGCTGTCCTGTATG-3= and antisense 5=-GCTTCTGCT-GCTTCCTTCACAC-3=.
Immunocytochemistry. mDCT and mDCT15 cells were treated with formalin and then permeabilized in 5% Triton X-100-containing PBS for 30 min. Rabbit polyclonal NCC primary antibody in PBS (1: 10,000) and anti-rabbit Alexa 647 secondary antibody (1:1,000) along with 4=,6-diamidino-2-phenylindole (1:1,000) and wheat germ agglutinin (1:1,000) were used to stain for NCC, cell nucli, and cell membranes, respectively. Fluorescent confocal microscopy was used to find a representative field at ϫ20 magnification.
Immunohistochemistry. Kidneys were fixed in 2.5% paraformaldehyde, cryopreserved with 15% sucrose, and embedded in Cryo-Gel (Instrumedics, St. Louis, MO) before being sectioned at 5 m.
Epitope retrieval was performed with 10 mM sodium citrate (pH 6.0), and sections were subsequently permeabilized with 0.25% Triton X-100 and 0.1% Tween 20 in PBS and blocked with 10% donkey serum. Mouse sections were incubated for 1 h at room temperature with rabbit anti-NCC primary antibody at 1:500. This was followed by Alexa fluor 594 donkey anti-rabbit secondary antibody (1:600, Invitrogen).
Dimerization assay. mDCT and mDCT15 lysates were harvested as previously described for immunoblots. Lysates were then either incubated with sample buffer containing ␤-mercaptoethanol (3% final concentration) at 70°for 25 min or sample buffer with no ␤-mercaptoethanol at room temperature. Lysates were then immunoblotted as described above.
Deglycosylation assay. mDCT and mDCT15 cells were incubated as described above. Cells were harvested, lysed using lysis buffer containing protease inhibitor, and homogenized by sonication on ice. Cell lysates were centrifuged briefly, and the supernatant was collected. The lysis product was treated with endoglycosidease H (Sigma) as per the manufacturer's protocol and incubated for 24 h before being immunoblotted as described above.
Protein preparation from the kidney cortex. Kidney cortical tissue was separated from the medullary portion of each kidney under magnification with a dissecting microscope and suspended in 20-fold excess (wt/v) TRIzol reagent (Invitrogen). The tissue was homogenized with 20 strokes of a 1-ml Dounce homogenizer on ice. The resulting sample was centrifuged at 500 g for 5 min and then at 10,000 g for 15 min. The supernatant was centrifuged at 100,000 g for 30 min. The resulting precipitate was suspended in 2.4 ml PBS containing 1 mM EDTA and 10% glycerol and stored at Ϫ80°C until use.
RESULTS

Subcloning and determination of NCC activity in mDCT15
cells. The original mDCT cell line (13-16, 23, 24) was subcloned to select for cells displaying greater NCC activity. Original mDCT cells were plated dilutely, and cloning rings were used to select individual colonies, which were then screened for NCC expression by real-time PCR. Those subcloned cells that demonstrated NCC expression approximately equal to or greater than the parent cell line were screened with a thiazide-sensitive 22 Na ϩ uptake assay to assess NCC activity. mDCT15 cells demonstrated considerably increased thiazidesensitive 22 Na ϩ uptake compared with the original mDCT cells (P Ͻ 0.01 compared with mDCT cells; Fig. 1A ). This increase was present in both uptakes performed with a traditional Cl Ϫ -free incubation and, importantly, in uptakes lacking a Cl Ϫ -free preincubation. A 22 Na ϩ uptake assay performed without Cl Ϫ in the uptake media showed minimal thiazide-sensitive 22 Na ϩ uptake, making this thiazide-sensitive uptake Cl Ϫ depen- Na ϩ and either vehicle or 1 mM metolazone. Radioactive uptake was determined as described in MATERIALS AND METHODS. Thiazidesensitive uptake was calculated as the difference in radiotracer uptake between the metolazone-containing and metolazone-free groups. Values are means Ϯ SE; n ϭ 4. *P Ͻ 0.01. B: mDCT15 cells were incubated in either CC or CF uptake medium to assess Cl Ϫ dependence. Thiazide-sensitive uptake was calculated as described above. Values are means Ϯ SE; n ϭ 6. *P Ͻ 0.01. C: mDCT15 cells were incubated in uptake medium containing metolazone in the indicated concentrations. Thiazide-sensitive uptake was calculated as described above. Values are means Ϯ SE; n ϭ 4. *P Ͻ 0.05. dent, the hallmark of NCC activity (Fig. 1B) . Furthermore, a thiazide dose-response curve of 22 
Na
ϩ uptake showed an IC 50 for metolazone of 3.47 ϫ 10 Ϫ6 M (Fig. 1C) , consistent with the expected value at a Na ϩ concentration of 140 mM (25) . The presence of NCC in mDCT15 cells was assessed via immunoblot analysis with an anti-NCC antibody developed by our laboratory. Immunoblot analysis and immunohistochemistry were done to confirm the specificity of the immunopurified antibody ( Fig. 2A) . The immunoblot analysis demonstrated that the antibody recognizes NCC in the mouse kidney cortex and mDCT15 cells with the signal blocked by a blocking peptide. Immunohistochemistry showed apical staining for NCC in DCT cells with adjacent non-DCT cells not staining. In the kidney cortex as well as in mDCT15 cells, two bands were visible. However, in the kidney cortex, the complexly glycosylated band at 135-155 kDa was the dominant band, whereas in mDCT15 cells, the high-mannose glycoprotein at 110 -115 kDa was the dominant band (Fig. 3A) . This pattern of in vitro systems for NCC displaying a functional high-mannose glycoprotein has been previously described in a study investigating the glycosylation of the cotransporter (21) . To confirm that the 113-kDa band in mDCT15 cells is a high-mannose NCC glycoprotein, mDCT15 lysates were exposed to endoglycosidase H, which deglycosylates high-mannose glycoproteins. Immunoblot analysis demonstrated that this resulted in the same 3-kDa shift from high-mannose glycoprotein to core unglycosylated NCC that was seen in the report characterizing the glycosylation of the cotransporter (21) .
In addition, the specificity of this thiazide-sensitive 22 Na ϩ uptake for NCC activity was confirmed by silencing NCC protein expression with RNA interference. RNA interference specific for NCC reduced NCC expression by 62 Ϯ 5% by densitometry (n ϭ 4, P Ͻ 0.01; Fig. 3B ). Thiazide-sensitive 22 Na ϩ uptake was similarly reduced by 53 Ϯ 3% compared with the control mDCT15 line transfected with nontargeting siRNA (n ϭ 4, P Ͻ 0.05; Fig. 3C ). Taking the increased thiazide-sensitive uptake, Cl Ϫ dependence, and appropriate metolazone IC 50 for NCC along with the dependence on NCC protein expression, it is clear that mDCT15 cells demonstrate significantly increased baseline NCC activity over traditional mDCT cells and do not require a Cl Ϫ -free preincubation for activity measurements.
mDCT15 cells display the characteristics of DCT2 cells. To ensure that these mDCT15 cells represented a physiologically relevant model, RT-PCR was performed to evaluate these cells for the expression of key NCC regulatory proteins and other proteins expected to be seen in the DCT. As shown in Fig. 4A , WNK1, WNK3, WNK4, and OSR were all expressed in Fig. 3 . NCC in mDCT15 cells is a high-mannose glycosylated protein and thiazide-sensitive Na ϩ uptake is dependent on NCC expression. A: lysates from mDCT15 cells were incubated for 3 h with endoglycosidase H (Endo H) at 65°C (ϩ), for 3 h at 65°C with vehicle (Ϫ), or were left untreated (control). Proteins were run on 6% SDS-PAGE gels, transferred to polyvinylidene difluoride membranes, and immunodetected with anti-NCC primary Ab. B: mDCT15 cells were treated with either nontargeting (NT) or NCC-specific short interfering (si)RNA (siNCC) as described in MATERIALS AND METHODS. Gene knockdown of NCC was confirmed via Western blot analysis (densitometry results are shown with the representative blot in the inset with matching actin). C: cells treated as in B were incubated in uptake medium, and uptake determination was performed as described above. Values are means Ϯ SE; n ϭ 4. *P Ͻ 0.01. mDCT15 cells. As described in detail below, SPAK protein was also expressed in these cells. Each of these kinases has been shown to modulate NCC activity and is thought to play a key role in its regulation. Furthermore, SGK-1, MR, and all three subunits of ENaC were also expressed. These are all characteristics of late DCT (DCT2) cells. These finding indicate that the mDCT15 cell line displays the characteristics of DCT2 cells and expresses the key regulators of NCC activity.
To ensure that NCC in the mDCT15 cell line behaves in a similar manner to that previously described for NCC in mDCT cells and oocytes, cells were treated with the phorbol ester 12-Otetradecanoylphorbol-13-acetate (TPA). TPA has been previously described to sharply decrease NCC activity in both oocytes and mDCT cells (23) . Administration of 100 nM TPA for 15 min decreased NCC activity by 98 Ϯ 5% in mDCT15 cells and by 102 Ϯ 8% in mDCT cells (n ϭ 6, P Ͻ 0.05 for both; Fig. 4B ).
NCC total abundance and surface expression is not altered in mDCT15 cells. Given the stark differences in NCC activity between mDCT15 cells and the original mDCT cells, NCC total abundance and NCC surface expression were examined to determine if differences in either of these factors could account for the enhanced NCC activity. No differences were seen in total NCC abundance between the two cell lines (n ϭ 5, P Ͼ 0.1; Fig. 5A ). Similarly, there were no significant differences in NCC surface expression between mDCT15 and mDCT cells (n ϭ 5, P Ͼ 0.1; Fig. 5A ).
An explanation for these findings was suggested by the immunohistochemistry results of the mDCT and mDCT15 cells (Fig. 5, B and C) . mDCT cells displayed a heterogeneous pattern of NCC staining (green), with areas of very high NCC expression, and cells that expressed very little NCC. This is in contrast to mDCT15 cells, which displayed a more uniform pattern of moderate staining for NCC. The combination of high and low NCC-expressing mDCT cells likely accounts for the average NCC expression in whole cell lysates being roughly equal to that of the more moderately but consistently NCCexpressing mDCT15 cells.
NCC in mDCT15 cells display increased SPAK, phosphorylated NCC, and NCC dimerization. Given the morphological and distribution differences of NCC in mDCT and mDCT15 cell lines, we examined the factors involved in the activation of surfaceexpressed NCC. First, SPAK expression and phosphorylation were investigated. SPAK has been shown to activate and phosphorylate NCC at three specific residues: Thr 46 (31) . Immunoblot analysis for total SPAK demonstrated the expression of almost twice as much SPAK in mDCT15 cells compared with mDCT cells (90 Ϯ 7% more, n ϭ 4, P Ͻ 0.05; Fig. 6A ). Immunoblot analysis using phospho-specific SPAK antibodies (SPAK 373) demonstrated a similar increase in mDCT15 cells compared with mDCT cells (n ϭ 4, P Ͻ 0.05; Fig. 6B ). While the absolute amount of phospho-SPAK was increased, the proportion of phospho-SPAK to total SPAK was unchanged.
Given that SPAK and phospho-SPAK were increased, we investigated the phosphorylation state of NCC in these cells. Immunoblot analysis for phospho-NCC using a Thr 53 -specific phospho-NCC antibody demonstrated more than twice the amount of phospho-NCC in mDCT15 cells compared with mDCT cells, providing a possible mechanism for the enhanced NCC activity (127 Ϯ 8% increase when controlled for total NCC, n ϭ 4, P Ͻ 0.05; Fig. 6C ).
As dimerized NCC is thought to be the predominant form of surface-expressed active NCC (6, 11), the relative amounts of dimerized NCC in mDCT15 and mDCT cells was determined. Our standard immunoblots could not demonstrate significant expression of oligomers because of strong reducing conditions. Therefore, to examine dimerization, we incubated mDCT15 and mDCT lysates using either standard procedures (heat and ␤-mercaptoethanol) or without ␤-mercaptoethanol at room temperature (Fig. 7) before immunoblot analysis. This revealed significant expression of a band at ϳ230 kDa in the absence of reducing agent, consistent with the expression of dimer. Immunoblot analysis for NCC showed a much greater amount of dimerized NCC in mDCT15 cells (n ϭ 4, P Ͻ 0.05; Fig. 7) . Based on the increased SPAK expression, NCC phosphorylation, and NCC dimerization, we conclude that mDCT15 cells display enhanced NCC activity due to increased amounts of SPAK, increased phosphorylated NCC, and a higher proportion of dimerized NCC.
Effect of WNK4 knockdown. Given that the mDCT15 cell line has significant baseline NCC activity and natively expresses WNK4, these cells provide an opportunity to assess the function of wild-type WNK4. To this end, small hairpin (sh)RNA specific for WNK4 was used to generate a stable mDCT15 cell line deficient in WNK4 expression (WNK4KD). WNK4 expression was assessed via real-time PCR to be reduced by 68 Ϯ 4% compared with mDCT15 cells expressing nontargeting shRNA (n ϭ 4, P Ͻ 0.05; Fig. 8A ). No change in the expression of SPAK, WNK1, or WNK3 was seen using real-time PCR (data not shown). Protein expression of WNK4 was decreased by 67 Ϯ 7% compared with controls, with no change in actin expression (n ϭ 5, P Ͻ 0.05; Fig. 8B ).
NCC activity, as measured by radiotracer uptake, was increased by 92 Ϯ 7% in WNK4KD cells compared with mDCT15 cells (n ϭ 6, P Ͻ 0.05; Fig. 8C ). Total NCC was unchanged, but NCC surface expression was increased in WNK4KD cells by 117 Ϯ 9% (n ϭ 4, P Ͻ 0.05; Fig. 8D ). These findings demonstrate that native WNK4 acts to suppress NCC surface expression at baseline.
DISCUSSION
The two most prominent sources of data concerning the mechanisms of molecular regulation of transport proteins in the kidney have been segment-specific microperfusion studies and assessment of regulation in tissue culture cell lines. The proximal tubule and collecting duct of the kidney are readily accessible for microperfusion studies, and multiple cell lines exist modeling these kidney segments. Channels have the added advantage of the utilization of electrophysiology to ease the study of alterations in function with certain stimuli. All of these factors have resulted in significantly more information being accumulated on other key transport proteins in the kidney. For example, there is a wealth of information regarding the regulation of ENaC. In contrast, NCC is an electroneutral cotransporter in a difficult to isolate nephron segment with a history of limited cell lines that demonstrate native expression of NCC. These circumstances have created a relative dearth of data on the regulation of NCC. Cell culture studies examining NCC can be divided into two groups: 1) models that did not assess function (and instead examined protein expression, surface expression, and/or phosphorylation of the cotransporter) or 2) models that measured NCC function (thiazidesensitive 22 Na ϩ uptake) after a Cl 15, 16, 23, 24, 31). To our knowledge, there are no published models of the mammalian DCT that measured NCC function without the use of Cl Ϫ -free preincubations, resulting in maximal activation of SPAK. Therefore, this is the only published model that is able to measure NCC function without perturbation of the critical SPAK/WNK regulatory system. The history of the regulation of transport proteins has demonstrated that regulation of surface expression and regulation of in situ transport activity are both important regulatory mechanisms. These disparate mechanisms of regulation of NCC have been seen in oocytes (8, 30) , but, due to lack of an appropriate model, have not been examined in mammalian cells. The ability to measure function directly in mammalian cells will be critically important as we unravel the hormonal and intracellular regulation of the cotransporter. In addition to the ability to measure function, we feel the other very important characteristic of a mammalian cell model is recapitulation of the molecular milieu of the DCT. Therefore, we fully examined the characteristics of this model compared with the DCT.
This model displays all of the characteristics of cells in the DCT2 in the mammalian kidney. Most importantly, they reflect the physiology of the mammalian DCT by expressing constitutively active NCC. While the dominant Na ϩ -reabsorptive pathway in the collecting duct (ENaC) is largely quiescent in animals on a standard Na ϩ diet (10, 29) , the dominant Na ϩ -reabsorptive pathway in the mammalian DCT (NCC) has a baseline level of activity on a standard Na ϩ diet (9) that is amenable to hormonal regulation (35) . In our model, NCC appears predominantly as a high-mannose glycoprotein running at ϳ113 kDa (Fig. 3A) . While this high-mannose glycoprotein is seen in native tissue (Fig. 3A) , the complexly glycosylated broad band at 135-160 kDa is the predominant band. However, in vitro systems often display significant appearance of a band at ϳ110 -115 kDa. In previous work describing the glycosylation of the transporter, we noted that this difference in glycosylation between oocyte expression systems and native tissue has been seen by others (21) . In that study, we investigated the dominant band seen in oocytes and determined that it represents a "high-mannose" glycoprotein that runs at 113 kDa. Endoglycosidase H, which only deglycosylates high-mannose glycoproteins, reduced this band to unglycosylated NCC at 110 kDa. As this is often the dominant band in oocytes, and the oocyte expression system provides very robust functional NCC, this high-mannose glycosylated NCC appears to be functional in oocytes, whereas unglycosylated NCC is not. There have been a number of recent reports examining NCC expressed in mammalian cells that appear to show the high-mannose glycoprotein as the dominant band (26, 32, 34) . Using endoglycosidase H, we confirmed that the dominant band in our system is a high-mannose glycoprotein (Fig. 3A) . The reason why in vitro systems often demonstrate expression of a high-mannose glycoprotein as opposed to the complexly glycosylated cotransporter remain unclear. While this should be considered in the interpretation of data, much knowledge has been gained concerning the regulation of NCC using such models. Here, we demonstrated that this highmannose glycoprotein gets to the surface, is phosphorylated, and is correlated with thiazide-sensitive 22 Na ϩ uptake (Figs. 5A, 3B, and 6C, respectively).
In our model, the actual functional characteristics of the cotransporter are consistent with all of the known characteristics of NCC. It is thiazide sensitive and Cl Ϫ dependent (Fig. 1) . To further assess the functional characteristics of the cotransporter, we measured the thiazide dose-response curve. We found that the IC 50 for metolazone was 3.47 ϫ 10 Ϫ6 (Fig. 1C) . In an oocyte study (25) , the IC 50 for metolazone for rat NCC was shown to be dependent on Na ϩ and Cl Ϫ concentrations. With Na ϩ and Cl Ϫ concentrations of 45 mM Cl Ϫ and 100 mM Na ϩ , the IC 50 is 3 ϫ 10 Ϫ7 . However, at 100 mM Na ϩ and Cl Ϫ (isotonic for Na ϩ and Cl Ϫ in amphibian oocytes), the IC 50 for metolazone is 2 ϫ 10 Ϫ6 . Based on these data, we feel the IC 50 in mDCT15 cells is appropriate for the 140 mM NaCl concentration we used. Further examination of known regulators of NCC revealed that phorbol esters cause greatly decreased surface expression of the cotransporter (Fig. 4B) , consistent with their effects in oocytes and precursor mDCT cells (23, 24) . Although this was compelling data indicating that we did assess NCC function with our thiazide-sensitive 22 Na ϩ uptakes, we felt that exploring the effect of knockdown of protein expression of NCC with specific siRNA in our thiazide-sensitive uptake would be the best possible validation of our model. Experiments demonstrated that knockdown of NCC protein correlated with similar decreases in thiazide-sensitive uptakes (Fig. 3, B and C) .
Native expression of the regulatory network is also a key component of an ideal model as it allows for physiological levels of expression and makes the model amenable to the powerful tool of shRNA knockdown to unravel the critical regulators. Therefore, we examined the expression of key DCT2 proteins, demonstrating that WNK1, WNK3, WNK4, OSR1, SGK-1, MR, and ENaC were all expressed in mDCT15 cells (Fig. 4A) . Additionally, we (1) recently demonstrated that Nedd4-2 is natively expressed in these cells and plays a role in ubiquitination and degradation of NCC. One of the most important and yet most controversial mechanisms for the regulation of NCC concerns WNK4. Initial studies (37) (38) (39) using transgenic models and the Xenopus laevis oocyte expression system indicated that WNK4 was inhibitory to NCC at baseline. Subsequently, studies (2, 34, 41) using mammalian cells transfected with NCC and WNK4 have confirmed that WNK4 inhibits NCC surface expression by inhibiting forward trafficking of NCC to the surface. These studies have not only confirmed inhibition of forward trafficking but have also begun to describe the key proteins involved in this process. These key studies have been reported by multiple groups and have supported the idea that WNK4 inhibits NCC at baseline. However, another theory has developed, based primarily on more recent whole animal transgenic studies (3, 28, 40) . This theory suggests that WNK4 stimulates NCC activity through phosphorylation of SPAK. One of the arguments proffered for results demonstrating the suppression of NCC activity is that the wealth of studies looking at WNK4 effects in cells have all been done in overexpression systems. Therefore, we investigated the effects of WNK4 on NCC in a natively expressing mammalian cell model. Using stable knockdown of WNK4 by shRNA in mDCT15 cells, we now demonstrate that inhibition of WNK4 results in increased NCC function and surface expression (Fig. 8) . This serves as further confirmation that WNK4 is inhibitory for NCC at baseline and suggests that the human disease FHHt is a loss of function mutation.
In contrast to WNK4, it is clear that SPAK stimulates NCC activity, primarily by direct phosphorylation of NCC in the amino-terminus (31) . Studies (8, 19, 30) with NCC expressed in oocytes have suggested that in situ NCC activity increases with phosphorylation. However, given the lack of mammalian models that can measure function of NCC, it has not been confirmed that phosphorylation stimulates NCC in mammalian cells by increasing surface expression or stimulating in situ activity of cotransporters already on the surface. Since our data indicate that greater phosphorylation of NCC in mDCT15 cells versus mDCT cells does not appear to result in greater surface expression, this suggests that the mechanism of stimulation by phosphorylation is in situ stimulation of activity (Fig. 5A) . We also found that increased phosphorylation appears to be associated with increased dimerization of NCC (Figs. 6 and 7) . Experiments using weak reducing conditions and cysteine linkage have demonstrated that NCC exists (both in vitro and in vivo) as a dimer and that the functional unit for NCC activity is a dimer (6, 11) . A recently suggested model of NCC regulation proposed that dimerization could be a consequence of phosphorylation (20) , although data to support that idea have not been published. Although our results do not demonstrate that dimerization is dependent on phosphorylation, they both appear to be correlated with increased activity of NCC without changes in surface expression. Further study will be necessary to clarify whether dimerization is dependent on the phosphorylation of NCC by SPAK. For these experiments, a mammalian cell model that can separate function from surface expression will be critical.
The mDCT15 model demonstrates many attributes that we feel will make it a valid and important tool to study NCC. The cells display native NCC function, as measured by thiazidesensitive, Cl Ϫ -dependent 22 Na ϩ uptake. RNA knockdown demonstrates that this function is dependent on NCC protein, and the dose-response curve for metolazone has an appropriate IC 50 . Furthermore, NCC in mDCT15 cells responds to phorbol esters, as previously described for rat NCC in oocytes and NCC in mDCT cells. These cells have baseline levels of activity and phosphorylation as seen in native tissue and have no requirement of Cl Ϫ -free incubations to measure function. They additionally have significant baseline dimerization of NCC. Finally, they display release of WNK4 inhibition of NCC by shRNA knockdown. We feel that this model is the most validated mammalian cell model for the molecular assessment of DCT2 physiology and compares favorably with previous studies that have attempted to measure NCC function in mammalian cells. A number of these studies (5, 7, 31) have reported mammalian cells heterologously expressing NCC. These studies obviously did not demonstrate native NCC expression or shRNA knockdown of NCC. Most of these studies were done before the discoveries of the key regulators and pathways for NCC regulation, and thus many of these validations were not feasible at the time. More recently, it has been demonstrated that in human embryonic kidney-293 cells transiently transfected with human NCC, there was very little thiazide-sensitive uptake compared with untransfected cells unless hypotonic low-Cl Ϫ preincubation was done (31) . This study was explicitly done to show the effect of low-Cl Ϫ incubation (activation of SPAK) on NCC function, and so none of the above validations were done.
The only DCT models that natively express NCC and have measured function are the precursor mDCT cells and mDCT15 cells. There are three studies in mDCT cells that examined changes in total Na ϩ uptake and one study that demonstrated thiazide-sensitive Na ϩ uptake (13, (15) (16) (17) . Our recent studies (23, 24) reported thiazide-sensitive 22 Na ϩ uptakes in mDCT cells grown in monolayers. We demonstrated a Cl Ϫ -dependent, thiazide-sensitive dose response and suppression by phorbol esters in mDCT cells. However, our new model demonstrates significant advantages compared with the mDCT cells from which they were derived. While the groups of mDCT and mDCT15 cells had similar average amounts of total and surface-expressed NCC (Fig. 5A) , mDCT15 cells had significantly increased baseline activity. Interestingly, immunocytochemistry results demonstrated that the expression of NCC in individual mDCT cells differed greatly. In mDCT cells, there were cells with essentially no expression of NCC and cells with massive expression of NCC (Fig. 5B) . In contrast, mDCT15 cells had a homogeneous appearance, with essentially all cells demonstrating a moderate level of expression. While the ideal model would also demonstrate easily obtainable images of apical localization of the cotransporter, no published model has yet demonstrated this. Since we have not yet established optimal conditions for x,z-sectioning of confocal images, we also have not yet been able to demonstrate this in our model.
Further analysis revealed that mDCT15 cells expressed a higher baseline expression of SPAK, resulting in a baseline degree of phosphorylation of NCC (Fig. 6A) , as seen in native tissue (3) . Ultimately, the more physiological baseline activity of these cells appears to be secondary to a greater level of the functional dimer (Fig. 7) . The totality of this data would suggest that NCC in overexpressing mDCT cells is unable to efficiently dimerize. It is unclear whether this is primarily due to less SPAK phosphorylation or to the heterogeneous nature of NCC expression in standard mDCT cells. However, it is clear, based on all of these studies, that mDCT15 cells represent a better, more physiological model of the mammalian DCT. While these distinct and critical differences are interesting and demonstrate clear advantages of our new model, ultimately what separates this new model from all other models (including mDCT cells) is the ability to measure function without perturbing the key WNK/SPAK pathway.
Importantly, all of these other models have been plagued by a major limitation that limits the ability to examine hormonal and mechanistic regulation of the cotransporter. They all used a Cl Ϫ -free incubation before fluxes were assessed. However, it has now become clear that Cl Ϫ -free or low-Cl Ϫ incubations activate the kinases SPAK and OSR, resulting in an increase in NCC function. In our experience, the absence of Cl Ϫ -free preincubation in standard mDCT cells resulted in a greatly decreased baseline activity of NCC, making functional assessment of NCC activity untenable. This also appears to be the case with human embryonic kidney-293 cells transfected with NCC (31) . Presumably, this has also been the case in all of the other reported models. To summarize, we now report a new model of the DCT that demonstrates the known characteristics of the DCT2. We feel that this system is the most validated mammalian cell model for molecular assessment of DCT2 physiology. The important work that can be accomplished in such a system represents a significant step forward toward unraveling the complex regulation of NCC.
